Abbott Boosts 2026 Profit Forecast Amid Diagnostics, Device Growth
Abbott raises its 2026 profit forecast as diagnostics and medical devices drive strong quarterly results, defying industry concerns.
Abbott Laboratories has raised its profit forecast for 2026, crediting robust demand in its diagnostics and medical devices segments. The announcement followed the company's impressive quarterly performance, which saw shares rise by 12%.
Diagnostics and Devices Drive Growth
The company's cancer diagnostics division has shown notable growth, largely due to the increased adoption of the Cologuard colorectal cancer screening test. This expansion follows Abbott's acquisition of Exact Sciences, enhancing its diagnostic capabilities. The diagnostics segment reported a 42% increase in sales, reaching $3.09 billion, surpassing the anticipated $3.02 billion.
Abbott's medical devices segment also contributed significantly, with sales rising 9% to $5.85 billion, slightly exceeding the projected $5.82 billion. These results helped the company counter concerns about declining surgical volumes and rising numbers of uninsured patients, trends highlighted by hospital operator HCA.
CEO Responds to Industry Concerns
Despite warnings from industry observers about potential impacts from changes in the Affordable Care Act (ACA) enrollment, Abbott's CEO Robert Ford dismissed these as a “flawed assumption.” Ford emphasized that Abbott's portfolio is closely tied to chronic conditions like diabetes, cardiovascular disease, and cancer, which are less likely to see insurance coverage lapses.
Abbott's performance stands in contrast to broader industry concerns about reduced procedure volumes, as flagged by HCA. The medtech sector has been under scrutiny, but Abbott's results have helped improve sentiment, particularly regarding its Exact Sciences acquisition.
Financial Outlook and Market Reaction
For the second quarter, Abbott reported an adjusted profit per share of $1.31, exceeding the consensus estimate of $1.28. Total revenue was $12.59 billion, slightly above the expected $12.5 billion. Looking ahead, Abbott has adjusted its profit forecast for 2026 to a range of $5.45 to $5.60 per share, up from a previous range of $5.38 to $5.58.
Shares of other medical technology firms, including Boston Scientific, Stryker, and Medtronic, also saw an uptick, each rising about 5% in morning trading. Analysts, such as William Blair's Brandon Vazquez, have noted that Abbott's strong performance could positively influence perceptions of its strategic acquisitions and market positioning.